癌_____癌，非小细胞肺；多西紫杉醇；健择；循证医学

多西紫杉醇联合健择治疗晚期非小细胞肺癌的系统评价

http://www.100md.com 《第四军医大学学报》 2004年第3期

癌,,癌，非小细胞肺；多西紫杉醇；健择；循证医学,0引言,1资料分析,2结果,3讨论,【参考文献】

     Chemotherapy of advanced NSCLC by docetaxel combined with gemcitabine: A systematic review

    WU YinSong, WANG Zhen

    Department of Orthopedics, Xijing Hospital, Fourth Millitary Medical University, Xi’an 710033, China

    【Abstract】 AIM: To study the efficiency and toxicities of docetaxelgemcitabine combination on advanced nonsmall cell lung cancer (NSCLC). METHODS: A systematic review was made on relevant clinical trials and the results were analyzed. RESULTS: We found that in firstline condition, the doublet is superior to platinumchemotherapy by reduced toxicities, but oneyear survival is not significantly improved; In the secondline condition, all 4 clinical trials show both improved survival and better tolerance. CONCLUSION: As an alternative solution to the traditional platinumbased chemotherapy of NSCLC, the docetaxelgemcitabine combination has superior efficiency and less toxicities.

    【Keywords】 carcinoma, nonsmallcelllung; docetaxel; gemcitabine; evidencebased medicine

    【摘要】目的：研究健择和多西紫杉醇联合方案治疗晚期非小细胞肺癌(NSCLC)的疗效. 方法：应用循证医学系统评价的方法，对目前两药合用的相关临床试验进行系统回顾 ......

百拇医药网 http://www.100md.com/html/DirDu/2006/02/19/87/15/46.htm

您现在查看是摘要页，全文长 10467 字符。